SCHEMBL4715382

SCHEMBL4715382

N#Cc1ccccc1Cn1c(C(=O)O)cc2c1ccc(=O)n2-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 1/20 0.47
NOX4 Q9NPH5 1/20 0.45
RXFP1 Q9HBX9 1/20 0.41
CCR2 P41597 2/20 0.41
ALDH1A1 P00352 3/20 0.40
NPSR1 Q6W5P4 1/20 0.40
THRB P10828 1/20 0.39
TSHR P16473 1/20 0.39
EGLN3 Q9H6Z9 1/20 0.38
PARG Q86W56 1/20 0.38
DPP4 P27487 2/20 0.38
GALR3 O60755 1/20 0.38
RAB9A P51151 1/20 0.38
CREBBP Q92793 1/20 0.38
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37
APEX1 P27695 1/20 0.37
APOBEC3A P31941 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4760166 0.91 NOX4 (0.43) FEN1NOX4RXFP1ALDH1A1NPSR1
SCHEMBL4789540 0.87 MAPT (0.49) FEN1NOX4RXFP1ALDH1A1NPSR1
SCHEMBL5119050 0.74 CCR2 (0.62) CCR2MAPT
SCHEMBL4711636 0.74 MEN1 (0.47) FEN1CCR2ALDH1A1THRBMEN1
SCHEMBL4714035 0.72 CCR2 (0.48) CCR2
SCHEMBL4714560 0.72 CCR2 (0.52) CCR2
SCHEMBL8688625 0.69 ALDH1A1 (0.60) FEN1NOX4RXFP1ALDH1A1NPSR1
SCHEMBL4716102 0.67 MAPT (0.57) ALDH1A1NPSR1TSHRMEN1POLB
SCHEMBL4715116 0.67 CCR2 (0.55) RXFP1CCR2MAPTTP53
SCHEMBL25391742 0.67 ALDH1A1 (0.49) FEN1ALDH1A1NPSR1TSHRGALR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 FEN1 2339/4885NOX4 865/4885RXFP1 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.